

<p style="text-align: center;"><b>LIST OF REFERENCES CITED BY APPLICANT</b>  <i>(Use several sheets if necessary)</i></p> <p style="text-align: center;">JUN 04 2001 U.S. PATENT &amp; TRADEMARK OFFICE O I P E C 113</p>					ATTY. DOCKET NO. 9632-006-999	APPLICATION NO. 09/724,406	
					APPLICANT Francisco et al.		
					FILING DATE November 28, 2000	GROUP 1642	
<b>U.S. PATENT DOCUMENTS</b>							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
AD	AA	5,165,923	November 24, 1992	Thorpe et al.			
	AB	5,866,372	February 2, 1999	Stein et al.			
↓	AC	6,033,876	March 7, 2000	Lemke et al.			
<b>FOREIGN PATENT DOCUMENTS</b>							
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION
							YES NO
<b>OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)</b>							
AD	Arndt et al., 1999, "A Bispecific Diabody That Mediates Natural Killer Cell Cytotoxicity Against Xenotransplanted Human Hodgkin's Tumors," <i>Blood</i> 94(8):2562-2568						
AE	Barth et al., 2000, "Ki-4(scFv)-ETA', a new recombinant anti-CD30 immunotoxin with highly specific cytotoxic activity against disseminated Hodgkin tumors in SCID mice," <i>Blood</i> 95:3909-3914						
AF	Bowen et al., 1993, "Functional Effects of CD30 on a Large Granular Lymphoma Cell Line, YT," <i>J. Immunol.</i> 151:5896-5906						
AG	Cerutti et al., 1998, "CD30 Is a CD40-Inducible Molecule that Negatively Regulates CD40-Mediated Immunoglobulin Class Switching in Non-Antigen-Selected Human B Cells," <i>Immunity</i> 9:247-256						
AH	Del Prete et al., 1995, "CD30-mediated Signaling Promotes the Development of Human T Helper Type 2-like T Cells," <i>J. Exp. Med.</i> 182:1655-1661						
AI	Dürkop et al., 1992, "Molecular cloning and expression of a new member of the nerve growth factor receptor family that is characteristic for Hodgkin's disease.,," <i>Cell</i> 68:421-427						
AJ	Engert et al., 1990, "Evaluation of Ricin A Chain-containing Immunotoxins Directed against the CD30 Antigen as Potential Reagents for the Treatment of Hodgkin's Disease," <i>Cancer Res.</i> 50:84-88						
AK	Engert et al., 1999, "Treatment of Advanced Hodgkin's Lymphoma: Standard and Experimental Approaches," <i>Seminars on Hematology</i> 36(3):282-289						
AL	Falini et al., 1992, " <i>In vivo</i> targeting of Hodgkin and Reed-Sternberg cells of Hodgkin's disease with monoclonal antibody Ber-H2 (CD30): immunohistological evidence," <i>British J. Haemat.</i> 82:38-45						
AM	Falini et al., 1992, "Response of refractory Hodgkin's disease to monoclonal anti-CD30 immunotoxin," <i>The Lancet</i> 339:1195-1196						
AN	Franke et al., 2000, "Characterization of the CD30L Binding Domain on the Human CD30 Molecule Using Anti-CD30 Antibodies," <i>Hybridoma</i> 19:43-48						

WAD	AO	Grell et al., 1999, "Induction of cell death by tumour necrosis factor (TNF) receptor 2, CD40 and CD30: a role for TNF-R1 activation by endogenous membrane-anchored TNF," <i>EMBO J.</i> 18(11):3034-3043
O I P E JUN 4 2001	AP	Gruss et al., 1994, "Pleiotrophic Effects of the CD30 Ligand on CD30-Expressing Cells and Lymphoma Cell Lines," <i>Blood</i> 83(8):2045-2056
O I P E JUN 4 2001	AQ	Hansen et al., 1991, "Antibody-enhanced shedding of the CD30 (Ki-1) antigen and biochemical analysis of its soluble form," <i>Immunobiol.</i> 183:214
O I P E JUN 4 2001	AR	Hecht et al., 1985, "Production and Characterization of a Monoclonal Antibody That Binds Reed-Sternberg Cells," <i>J. Immunol.</i> 134(6):4231-4236
O I P E JUN 4 2001	AS	Horn-Lohrens et al., 1995, "Shedding of the Soluble Form of CD30 From the Hodgkin-Analogose Cell Line L540 is Strongly Inhibited by a new CD30-Specific Antibody (Ki-4)," <i>Int. J. Cancer</i> 60:539-544
O I P E JUN 4 2001	AT	Hsu et al., 1987, "Effect of Monoclonal Antibodies Anti-2H9, Anti-IRac, and Anti-HeFi-1 on the Surface Antigens of Reed-Sternberg Cells," <i>JNCI</i> 79(5):1091-1099
	AU	Hübinger et al., 1999, "The tyrosine kinase NPM-ALK, associated with anaplastic large cell lymphoma, binds the intracellular domain of the surface receptor CD30 but is not activated by CD30 stimulation," <i>Exp. Hematol.</i> 27:1796-1805
	AV	Josimovic-Alasevic et al., 1989, "Ki-1 (CD30) antigen is released by Ki-1-positive tumor cells in vitro and in vivo. I. Partial characterization of soluble Ki-1 antigen and detection of the antigen in cell culture supernatants and in serum by an enzyme-linked immunosorbent assay," <i>Eur. J. Immunol.</i> 19:157-162
	AW	Leca et al., 1994, "A Monoclonal Antibody to the Hodgkin's Disease-Associated Antigen CD30 Induces Activation and Long-Term Growth of Human Autoreactive $\gamma\delta$ T Cell Clone," <i>Cell. Immunol.</i> 156:230-239
	AX	Masuda et al., 1998, "Dual action of CD30 antigen: Anti-CD30 antibody induced apoptosis and interleukin-8 secretion in Ki-1 lymphoma cells," <i>Int. J. Hematol.</i> 67:257-265
	AY	May et al., 1990, "Evaluation of ricin A chain-containing immunotoxins directed against different epitopes on the delta-chain of cell surface-associated IgD on murine B cells," <i>J. Immunol.</i> 144:3637-3642
	AZ	Mir et al., 2000, "Differential effects of CD30 activation in anaplastic large cell lymphoma and Hodgkin disease cells," <i>Blood</i> 96(13):4307-4312
	BA	Nawrocki et al., "Biochemical and Structural Properties of a Hodgkin's Disease-Related Membrane Protein," <i>J. Immunol.</i> 141:672-680
	BB	Pallesen, 1990, "The diagnostic significance of the CD30 (Ki-1) antigen," <i>Histopathology</i> 16:409-413
	BC	Powell et al., 1998, "Construction and expression of a soluble form of human CD30 ligand with functional activity," <i>J. Leukocyte Biology</i> 63:752-757
	BD	Press et al., 1988, "Ricin A-chain containing immunotoxins directed against different epitopes on the CD2 molecule differ in their ability to kill normal and malignant T cells," <i>J. Immunol.</i> 141:4410-4417
	BE	Renner et al., 2000, "Initiation of humoral and cellular immune responses in patients with refractory Hodgkin's disease by treatment with an anti-CD16/CD30 bispecific antibody," <i>Cancer Immunol. Immunother.</i> 49:173-180
	BF	Schwab et al., 1982, "Production of a monoclonal antibody specific for Hodgkin and Sternberg-Reed cells of Hodgkin's disease and a subset of normal lymphoid cells," <i>Nature</i> 299:65-67
	BG	Schwarting et al., 1989, "BER-H2: a new anti-Ki-1 (CD30) monoclonal antibody directed at a formol-resistant epitope," <i>Blood</i> , <i>Blood</i> 74:1678-1689
↓	BH	Smith et al., 1993, "CD30 Antigen, a Marker for Hodgkin's Lymphoma, Is a Receptor Whose Ligand Defines an Emerging Family of Cytokines with Homology to TNF," <i>Cell</i> 73:1349-1360

<i>NAD</i>	BI	Tian et al., 1995, "In vivo Antitumor Effects of Unconjugated CD30 Monoclonal Antibodies on Human Anaplastic Large-Cell Lymphoma Xenografts," <i>Cancer Res.</i> 55:5335-5341
<i>O I P E S O C T S</i> JUN 04 2001 PATENT & TRADEMARK OFFICE	BJ	Tsutsumi et al., 2000, "Site-specific chemical modification with polyethylene glycol of recombinant immunotoxin anti-Tac(Fv)-PE38 (LMB-2) improves antitumor activity and reduces animal toxicity and immunogenicity," <i>Proc. Natl. Acad. Sci. USA</i> 97:8548-8553
	BK	Tutt et al., 1998, "Monoclonal antibody therapy of B cell lymphoma: signaling activity on tumor cells appears more important than recruitment of effectors," <i>J. Immunol.</i> 161:3176-3185
EXAMINER <i>Notchie A. Orr</i>	DATE CONSIDERED <i>7-5-01</i>	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.